SEC Filings
LivaNova Shares Jump 20% Even As Heart-Lung Unit's Profit Falls On A $34.0 Million Litigation Charge
Cardiopulmonary segment income fell to $7.6 million, but LivaNova raised its 2026 outlook.
LIVN
LivaNova (LIVN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
LivaNova Calls Sleep Apnea Market Slowdown 'Temporary' As It Plans A Limited 2027 Launch
LivaNova's CFO blames coding and reimbursement confusion for slower growth in nerve-stimulation sleep apnea therapy, and raised 2026 guidance to 9% to 10%.
Earnings
LivaNova Raises 2026 Outlook After Heart-Surgery And Epilepsy Devices Each Grow Over 10%
The device maker lifted its adjusted earnings forecast to $4.40 to $4.50 a share, while third-quarter diluted earnings per share fell to $0.11.